This summer, shoppers across the U.S. can make a lasting impact for kids and young adults living with neuromuscular diseases. The Muscular Dystrophy Association (MDA) is partnering with more than ...
ETHealthworld.com brings latest muscular dystrophy news, views and updates from all top sources for the Indian Health ...
Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company developing next-generation cardiovascular therapeutics, and its clinical development division Sardocor, today announced that the U.S.
Duchenne muscular dystrophy has several approved drugs, including a gene therapy that provides children who have the rare, inherited muscle-wasting disease the option of a one-time treatment. But each ...
Emma Ciafaloni, MD, FAAN, dives into the latest developments in gene therapy for muscular dystrophies, focusing on Duchenne muscular dystrophy, and discusses challenges, genetic causes, and the ...
TOKYO--(BUSINESS WIRE)--Duchenne Muscular Dystrophy (DMD) patients showed signs of disease progress slowing down, after oral consumption of Neu REFIX ß-glucan for 45 days along with routine ...
A new mouse model mimicking the liver symptoms of myotonic dystrophy type 1 -- the most prevalent form of adult-onset muscular dystrophy -- provides insight into why patients develop fatty liver ...
Roche Holding said it would start a late-stage study for a gene therapy for Duchenne muscular dystrophy to seek approval in the European Union after drug regulators in the bloc turned it down last ...
El Paso Matters on MSNOpinion
Opinion: FDA delays on rare disease drugs put my son and other children with rare diseases at risk
An El Paso mother of a child with Duchenne muscular dystrophy says FDA delays have cost critical time for children with rare ...
Capricor Therapeutics has presented positive long-term data from its HOPE-2 clinical trial at the 2025 Muscular Dystrophy Association Conference, indicating that its leading treatment, deramiocel, can ...
The degree to which novel value elements such as insurance value impact estimated treatment value for rare, severe genetic diseases such as Duchenne muscular dystrophy is unclear. Objectives: To ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results